Can genetic therapy help kids with Angelman syndrome overcome seizures?

November 20, 2018 by Mark Derewicz, University of North Carolina Health Care
Credit: CC0 Public Domain

Angelman syndrome is a genetic disease with no cure. Children grow up with severe intellectual disabilities and a range of other problems, arguably the worst of which are epileptic seizures. Now scientists at the UNC School of Medicine have found evidence that genetic therapy may prevent the enhanced seizure susceptibility.

Published in the Journal of Clinical Investigation, the research marks the first time scientists were able to reduce seizure susceptibility in mice by activating a dormant copy of the UBE3A gene so it could replace the faulty mutant version. While replacing the faulty gene in juveniles reduced seizures, replacing the faulty gene in adult mice had no effect.

The UNC scientists also found evidence that the loss of this gene in Angelman syndrome promotes seizures by impairing the normal activity of inhibitory neurons—cells that normally keep brain circuits from being overstimulated.

"These findings should be very useful in the development and testing of therapies for Angelman syndrome," said senior author Benjamin D. Philpot, Ph.D., Kenan Distinguished Professor in the Department of Cell Biology and Physiology, associate director of the UNC Neuroscience Center, and member of the UNC Autism Research Center.

Angelman syndrome, named for the pediatrician who first described it in 1965, afflicts roughly one in 20,000 people, which implies that there are more than 16,000 people with the syndrome in the United States alone. The syndrome is caused by the loss of function of a single gene, UBE3A, but with an odd twist: the mutant or deleted copy of UBE3A is the one inherited from the patient's mother. This maternal copy is crucial in neurons because—for reasons still unknown—the paternal copy of UBE3A is silenced in these cells via a mechanism called genomic imprinting.

UBE3A encodes a protein that works in an important cellular waste-disposal and gene-regulating system. Precisely how the absence of this protein in neurons causes Angelman syndrome has never been clear. Even so, scientists have been working on candidate therapies to restore UBE3A activity in neurons, thereby preventing or reversing some or all of the features of the disease. Among these features is epilepsy, which afflicts about 90 percent of Angelman syndrome patients, who typically do not respond well to standard anti-seizure medications.

Some aspects of the disease reflect abnormal prenatal and early postnatal development, and may never be reversible with treatments that start years after birth. But epilepsy often doesn't start in Angelman patients until age 2 or 3, suggesting that early life replacement of UBE3A might cure it or prevent it. Philpot and colleagues decided to investigate how early the gene reinstatement needed to take place. They took advantage of an Angelman syndrome mouse model, in which researchers inserted a working copy of the UBE3A gene that would lie dormant in brain cells until scientists turned it on with a chemical switch.

The scientists found that switching on UBE3A failed to prevent or reverse the high susceptibility to seizures in adult Angelman mice. However, switching on the gene when the mice were just three weeks old made them as resistant to seizures as ordinary mice.

"Three weeks of age for a mouse corresponds to early childhood for a human, so this suggests that there may be a window of opportunity in childhood for the prevention of Angelman syndrome epilepsy," said first author Bin Gu, Ph.D., a postdoctoral researcher in the Philpot Lab who performed most of the key experiments.

Another big question for Angelman syndrome researchers has to do with the neurons affected by the disease. Philpot wondered, to treat the condition successfully, would UBE3A activity need to be restored in all types of neurons or just in some?

Philpot's team removed functional UBE3A from excitatory neurons—which trigger activity in connected neurons—and observed that the resulting mice were unaffected. Then they blocked the gene just in inhibitory neurons, whose activity normally quiets and regulates connected neurons, thereby preventing the neural hyperactivity that can trigger seizures. With UBE3A gone from the inhibitory neurons, the mice became even more susceptible to seizures than if UBE3A were absent from all neurons.

"This result implies that if you want to limit epilepsy in Angelman syndrome, you'll need at least to restore the function of UBE3A in inhibitory neurons," Philpot said.

The researchers gained another clue to the mechanism of Angelman syndrome seizures when they examined the brains of the seizure-prone mice, particularly in an area of the brain known as the hippocampus. They detected an abnormal accumulation of perineuronal nets (PNNs) - structures that surround neurons and block them from making new connections. Abnormal PNN formation has previously been linked to seizures. The scientists found that the abnormal PNN deposition did not occur in the young where UBE3A activity had been restored.

"We can now think of these abnormal PNNs as biomarkers for enhanced seizure susceptibility," Philpot said. "We now want to determine if these structures actually cause susceptibility, for example by disrupting the connections that inhibitory normally would make in this brain region."

Philpot and collaborators at UNC, along with other researchers elsewhere, are working on potential Angelman treatments, including drugs that would activate the previously silenced paternal copy of UBE3A in brain cells.

Explore further: Video: Can CRISPR/Cas9 help cure Angelman syndrome?

More information: Bin Gu et al, Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice, Journal of Clinical Investigation (2018). DOI: 10.1172/JCI120816

Related Stories

Video: Can CRISPR/Cas9 help cure Angelman syndrome?

July 11, 2018
We all have a gene called UBE3A, and when the copy we inherit from our mother works normally, our brain develops properly.

Neuron type-specific gene loss linked to Angelman syndrome seizures

March 24, 2016
The gene UBE3A plays a critical role in early neurological development. If UBE3A is overexpressed - or if the enzymatic function of UBE3A protein is hyperactive - autism ensues. A lack of functional UBE3A causes Angelman ...

Researchers account for the complex symptoms of Angelman syndrome

April 20, 2018
A research group at the Faculty of Science and Technology of the UPV/EHU-University of the Basque Country has managed to identify the changes in the proteins altered by the UBE3A enzyme, which is responsible for Angelman ...

Brain cell activity imbalance may account for seizure susceptibility in Angelman syndrome

June 6, 2012
New research by scientists at the University of North Carolina School of Medicine may have pinpointed an underlying cause of the seizures that affect 90 percent of people with Angelman syndrome (AS), a neurodevelopmental ...

New discovery could lead to treatment for Angelman syndrome

December 21, 2011
Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

Scientists pinpoint how a single genetic mutation causes autism

August 6, 2015
Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show ...

Recommended for you

How returning to a prior context briefly heightens memory recall

December 11, 2018
Whether it's the pleasant experience of returning to one's childhood home over the holidays or the unease of revisiting a site that proved unpleasant, we often find that when we return to a context where an episode first ...

Neurons in the brain work as a team to guide movement of arms, hands

December 11, 2018
The apparent simplicity of picking up a cup of coffee or turning a doorknob belies the complex sequence of calculations and processes that the brain must undergo to identify the location of an item in space, move the arm ...

The importins of anxiety

December 11, 2018
According to some estimates, up to one in three people around the world may experience severe anxiety in their lifetime. In a study described today in Cell Reports, researchers at the Weizmann Institute of Science have revealed ...

The richer the reward, the faster you'll likely move to reach it, study shows

December 11, 2018
If you are wondering how long you personally are willing to stand in line to buy that hot new holiday gift, scientists at Johns Hopkins Medicine say the answer may be found in the biological rules governing how animals typically ...

Using neurofeedback to prevent PTSD in soldiers

December 11, 2018
A team of researchers from Israel, the U.S. and the U.K. has found that using neurofeedback could prevent soldiers from experiencing PTSD after engaging in emotionally difficult situations. In their paper published in the ...

Study: Age, race differences determine risk of stroke in women and men

December 11, 2018
A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.